Very selective ..that tell you all you need to know"KCSA has a deep and abiding commitment to supporting the broader psychedelics research community. We are very selective in who we work with and believe the Mydecine team is doing innovative work that needs to have a spotlight shined upon it," said Lewis Goldberg, managing partner, KCSA, who leads the communication team. "We have followed Mydecine's progress and growth closely and believe in its approach and vision for advancing our understanding and delivery of psychedelics and psychedelic-assisted psychotherapy to treat PTSD and a host of other conditions."